These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34710258)

  • 21. Low Rate of Cancer Events After Partial Nephrectomy for Renal Cell Carcinoma: Clinicopathologic Analysis of 1994 Cases with Emphasis on Definition of "Recurrence".
    Bertolo R; Nicolas M; Garisto J; Magi-Galluzzi C; McKenney JK; Kaouk J
    Clin Genitourin Cancer; 2019 Jun; 17(3):209-215.e1. PubMed ID: 31000486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma.
    Han WK; Alinani A; Wu CL; Michaelson D; Loda M; McGovern FJ; Thadhani R; Bonventre JV
    J Am Soc Nephrol; 2005 Apr; 16(4):1126-34. PubMed ID: 15744000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
    Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
    Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of Percutaneous Thermal Ablation for Biopsy-Proven T1a Renal Cell Carcinoma in Patients With Other Primary Malignancies.
    Abdelsalam ME; Sabir SH; Ba SBK; Karam JA; Matin SF; Wood CG; Ahrar K
    AJR Am J Roentgenol; 2021 Jul; 217(1):157-163. PubMed ID: 33909469
    [No Abstract]   [Full Text] [Related]  

  • 25. [Predicting postoperative recurrence of renal cell carcinoma using serum vascular endothelial growth factor].
    Fujita N; Okegawa T; Tambo M; Shishido T; Nutahara K; Higashihara E
    Nihon Hinyokika Gakkai Zasshi; 2013 Jan; 104(1):1-5. PubMed ID: 23457926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of urinary cell-free miR-210 as a potential tool of liquid biopsy for clear cell renal cell carcinoma.
    Li G; Zhao A; Péoch M; Cottier M; Mottet N
    Urol Oncol; 2017 May; 35(5):294-299. PubMed ID: 28089386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma.
    Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y
    Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urinary Human Kidney Injury Molecule1- (hKIM1-) is not Increased in Patients with Renal Cell Carcinoma.
    Bialek L; Poletajew S; Niemczyk M; Czerwinska K; Nowak M; Sadowska A; Borkowski T; Radziszewski P; Dobruch J; Kryst P
    Urol J; 2020 Oct; 17(6):664-666. PubMed ID: 33000456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor size, stage and grade alterations of urinary peptidome in RCC.
    Chinello C; Cazzaniga M; De Sio G; Smith AJ; Grasso A; Rocco B; Signorini S; Grasso M; Bosari S; Zoppis I; Mauri G; Magni F
    J Transl Med; 2015 Oct; 13():332. PubMed ID: 26482227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma.
    Lee BH; Feifer A; Feuerstein MA; Benfante NE; Kou L; Yu C; Kattan MW; Russo P
    Eur Urol Focus; 2018 Jan; 4(1):100-105. PubMed ID: 28753780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of urinary glycosaminoglycan excretion in patients with renal cell carcinoma.
    Sarica K; Türkölmez K; Soygür T; Ozer G; Yaman MO; Baltaci S; Bedük Y; Müftüoğlu YZ
    Eur Urol; 1997; 31(1):54-7. PubMed ID: 9032535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urinary aquaporin 1 and perilipin 2: Can these novel markers accurately characterize small renal masses and help guide patient management?
    Song JB; Morrissey JJ; Mobley JM; Figenshau KG; Vetter JM; Bhayani SB; Kharasch ED; Figenshau RS
    Int J Urol; 2019 Feb; 26(2):260-265. PubMed ID: 30467901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction and diagnosis of renal cell carcinoma using nuclear magnetic resonance-based serum metabolomics and self-organizing maps.
    Zheng H; Ji J; Zhao L; Chen M; Shi A; Pan L; Huang Y; Zhang H; Dong B; Gao H
    Oncotarget; 2016 Sep; 7(37):59189-59198. PubMed ID: 27463020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microscopic venous invasion in renal cell carcinoma as a predictor of recurrence after radical surgery.
    Ishimura T; Sakai I; Hara I; Eto H; Miyake H
    Int J Urol; 2004 May; 11(5):264-8. PubMed ID: 15147540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of tumor histology and grade on treatment success of percutaneous renal cryoablation.
    Beksac AT; Rivera-Sanfeliz G; Dufour CA; Nseyo U; Hamilton Z; Berquist SW; Hassan AE; Raheem OA; Wang S; Wake RW; Gold RE; Derweesh IH
    World J Urol; 2017 Apr; 35(4):633-640. PubMed ID: 27484204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncologic Surveillance After Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach.
    Stewart-Merrill SB; Thompson RH; Boorjian SA; Psutka SP; Lohse CM; Cheville JC; Leibovich BC; Frank I
    J Clin Oncol; 2015 Dec; 33(35):4151-7. PubMed ID: 26351352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low predictive accuracy of the Kattan postoperative nomogram for renal cell carcinoma recurrence in a population of French patients.
    Hupertan V; Roupret M; Poisson JF; Chretien Y; Dufour B; Thiounn N; Mejean A
    Cancer; 2006 Dec; 107(11):2604-8. PubMed ID: 17075871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contralateral metachronous tumor occurrence is more frequently associated with distant metastases or postoperative intrarenal recurrence in renal cell carcinoma patients.
    Amano H; Kondo T; Hashimoto Y; Kobayashi H; Iizuka J; Shimada K; Nakazawa H; Ito F; Tanabe K
    Int J Urol; 2010 Jul; 17(7):615-22. PubMed ID: 20482658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.